1.
|
Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 0 to 30
Sponsor: Other
Protocol IDs: EUDRACT 2005-002618-40, BfArM-4030755, EC-105/05, DKS 2006.01, DK 2008.17, NCT00749723
|
|
2.
|
Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 18 to 59
Sponsor: Other
Protocol IDs: M09TNM, 2009-015238-31, NCT01057069
|
|
3.
|
Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Approved-not yet active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 12154, NCT01438112
|
|
4.
|
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: Under 3
Sponsor: NCI
Protocol IDs: COG-ACNS0334, ACNS0334, NCT00336024
|
|
5.
|
Phase: Phase III
Type: Supportive care, Treatment
Status: Active
Age: 1 to under 22 at first relapse
Sponsor: NCI
Protocol IDs: COG-ASCT0431, ASCT0431, COG-PBMTC-ONCO51, NCT00382109
|
|
6.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 10 and under
Sponsor: NCI
Protocol IDs: COG-ARET0321, ARET0321, NCT00554788
|
|
7.
|
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 21 and under at the time of definitive surgery
Sponsor: NCI
Protocol IDs: COG-ACNS0333, ACNS0333, NCT00653068
|
|
8.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: N12OLG, 2012-000838-19, NCT01646034
|
|
9.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: Under 55
Sponsor: NCI, Other
Protocol IDs: CDR0000525755, MSKCC-06125, NCT00423514
|
|
10.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 to 60
Sponsor: Other
Protocol IDs: EK126092000, NCT00460629
|
|
11.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 3 to 50
Sponsor: Other
Protocol IDs: MYS-07-HMO-CTIL, NCT00984412
|
|
12.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 to 54
Sponsor: Other
Protocol IDs: BELEHAPLO-1412001, NCT01220544
|
|
13.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 10 to 69
Sponsor: Other
Protocol IDs: 2006LS032, UMN-MT2005-21, UMN-0608M90586, UMN-2006LS032, NCT00432094
|
|
14.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 6 months to 21 years
Sponsor: Other
Protocol IDs: NYU 05-40 H12853, PBMTC ONC-032P, NCT00528437
|
|
15.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: SCCC-102007-035, 102007-035, SCCC-02F07, NCT00621036
|
|
16.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 to 65
Sponsor: Other
Protocol IDs: GELTAMO-Z-RIC-Allo, EuDRACT nº:2007-003302-10, NCT00644371
|
|
17.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 to 65
Sponsor: Other
Protocol IDs: ZNS-00465, NCT00647049
|
|
18.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 to 70
Sponsor: Other
Protocol IDs: 08-087, NCT00739141
|
|
19.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: Under 60
Sponsor: Other
Protocol IDs: 2008-0363, NCT00857389
|
|
20.
|
Phase: Phase II
Type: Supportive care, Treatment
Status: Active
Age: 14 to 55
Sponsor: NCI, Other
Protocol IDs: FHCRC-2222.00, P30CA015704, P01CA018029, IR-6907, CDR0000644201, 0903004832, NCT00914940
|
|
21.
|
Phase: Phase II
Type: Treatment
Status: Approved-not yet active
Age: 18 to 70
Sponsor: Other
Protocol IDs: 07CC12, REC - 07/H0808/193, EudraCT - 2007-001657-26, NCT00916045
|
|
22.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 5 to 19
Sponsor: Other
Protocol IDs: PNET HR+ 5, CSET 1329, NCT00936156
|
|
23.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 to 65
Sponsor: Other
Protocol IDs: EudraCT 2007-006016-33, NCT00961142
|
|
24.
|
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 0 to 65
Sponsor: Other
Protocol IDs: 2009-0266, NCT01010217
|
|
25.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 0 to 26
Sponsor: Other
Protocol IDs: L 10,321, NYMC 525, NCT01049854
|
Mobile | Español
